Abstract
The disease-free survival of patients with myeloma and severe renal failure after high-dose melphalan and autologous stem cell rescue is similar to those with normal renal function at the time of the autograft. However, recovery of renal function after intensive treatment is uncommon and patients with end-stage renal failure continue to be dialysis-dependent. We report two patients with myeloma who required regular haemodialysis from diagnosis, but became dialysis-independent after a high-dose melphalan autograft. Thus, in some patients, renal function may be partially salvageable despite the requirement for dialysis at the time of autografting.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure Br J Haematol 2001 114: 822 829
Sirohi B, Powles R, Kulkarni S et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m2 as a surrogate marker of outcome in patients with myeloma Br J Cancer 2001 85: 325 332
Sirohi B, Powles R, Treleaven J et al. The implication of compromised renal function at the time of presentation in myeloma: a single centre study of 251 patients Blood 1999 94: (Suppl. 1) 575a
Alexanian R, Barlogie B, Dixon D . Renal failure in myeloma. Pathogenesis and prognostic implications Arch Intern Med 1990 150: 1693 1695
Ballester OF, Tummala R, Jansen WE et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency Bone Marrow Transplant 1997 20: 653 656
Sirohi B, Powles R, Kulkarni S et al. Feasibility of administering high-dose melphalan (HDM) with autotransplantation in myeloma patients on dialysis Blood 2001 98: 5381 (Abstr.)
Goldschmidt H, Lannert H, Bommer J et al. Multiple myeloma and renal failure Nephrol Dial Transplant 2000 15: 301 304
Powles R, Raje N, Milan S et al. Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment Bone Marrow Transplant 1997 20: 435 443
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tauro, S., Clark, F., Duncan, N. et al. Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure. Bone Marrow Transplant 30, 471–473 (2002). https://doi.org/10.1038/sj.bmt.1703713
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703713
Keywords
This article is cited by
-
Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option
Bone Marrow Transplantation (2022)
-
Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure
Bone Marrow Transplantation (2015)
-
Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?
Bone Marrow Transplantation (2013)
-
Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease
Annals of Hematology (2010)